What getting trained in Challenger Selling and then getting reorganized out of my job taught me about the gap between healthcare strategy and the clinical conversation
I spent a year learning how to sell differently.
As a Business Development Manager in the life sciences industry, I was trained extensively in the Challenger methodology. The investment wasn't a one-day workshop or a few online modules. It was a year of learning how to understand a customer's world, identify insights they might not have considered, challenge assumptions, and create conversations around problems rather than products.
Six months after that training was completed, I was reorganized out of my position.
Suddenly, I was on the other side of the commercial conversation.
I was the person looking for the next opportunity.
And that experience exposed something I hadn't fully appreciated while I was inside the organization.
When I talked to hiring teams about Challenger Selling, I could explain the methodology. I could talk about teaching, tailoring, taking control of a conversation, and creating customer insight.
But increasingly, I found myself competing against candidates who had spent years in the room.
Nurses.
Physician assistants.
Nurse practitioners.
DOs.
MDs.
For clinical commercial positions, the value of having actually been in the clinical environment is obvious.
I understood why companies wanted it.
But I also started asking myself a different question:
If I can't compete with a clinician on the fact that I've been in the exam room, what can I bring into that room that a traditional sales approach doesn't?
That question eventually led me somewhere unexpected.
Public-health data.
The Insight I Couldn't Stop Thinking About
Healthcare companies already have access to enormous amounts of information about the populations they serve.
State departments of health publish disease prevalence, hospitalization, mortality, screening, cancer staging, and health-disparity data.
The CDC publishes extensive population-health information.
Cancer registries track diagnosis and staging.
CMS provides enormous amounts of information about healthcare utilization.
Hospitals publish Community Health Needs Assessments.
County-level organizations publish health rankings and social determinants of health.
And pharmaceutical and medical-device companies already use much of this information internally.
Market-access teams use it.
HEOR teams use it.
Commercial analytics teams use it.
Strategic-account teams use it.
Companies use population data to size markets, identify opportunities, prioritize territories, understand healthcare utilization, and build strategic plans.
But I began wondering:
What happens if we take some of that intelligence out of the strategy meeting and put it into the HCP conversation?
Not as another product slide.
Not as another statistic designed to support a marketing claim.
But as the beginning of a question.
What If the First Question Isn't About the Product?
Consider the conventional healthcare sales conversation.
A representative walks into a physician's office and eventually gets to:
“Our product is more accurate.”
Or:
“Our clinical data demonstrate better outcomes.”
Or:
“Our product has advantages over the incumbent.”
Those may all be legitimate reasons to choose a product.
But they start with the product.
The physician is immediately being asked to evaluate something.
Compare that with:
“The state data show that this region has a substantially higher rate of late-stage diagnosis than the state average. Does that match what you're seeing in your patients?”
That question doesn't require the physician to agree with you.
It doesn't require them to like your product.
It doesn't even mention your product.
It asks them to think about their patients.
And suddenly, the conversation is about their world.
That's where Challenger Selling becomes much more interesting.
The Challenger Connection
The Challenger Sale isn't simply about having better information.
It's about teaching the customer something that changes how they understand a problem.
Traditional Challenger conversations often begin with an insight about the customer's business.
Healthcare gives us another potential source of insight:
the population surrounding the customer.
That creates a different pathway.
Traditional product-centered conversation
Product → Differentiation → Competitor → Decision
Population-driven Challenger conversation
Population → Local pattern → Clinical experience → Question → Need → Solution
The product hasn't disappeared.
It has simply moved later.
The salesperson first creates a reason to explore a problem.
Then the HCP helps determine whether that problem actually exists in their practice.
Only then does the solution become relevant.
I Think We're Missing a Last Mile
This is not an argument that the life sciences industry isn't using population-health data.
It absolutely is. It is why they choose specific regions for Clinical Account Specialists (CAS) or similar positions.
The interesting question is where that data stops.
A sophisticated organization might move information through:
Public health data
↓
Market intelligence
↓
Strategic planning
↓
Territory prioritization
↓
Sales representative
The representative memorizes the battle sheet. And then the final customer interaction can revert to:
“Here's why our product is better.”
That's the disconnect I'm interested in.
The organization may understand the population extraordinarily well.
But the representative may not use that understanding to change the first question they ask the individual HCP.
The intelligence makes it all the way through the sales organization, but not necessarily all the way into the conversation.
Virginia Makes the Idea Concrete
I started looking at what was already publicly available through the Virginia Department of Health.
There is far more there than I initially expected.
Virginia publishes information through resources including cancer staging and incidence data, chronic-disease information, health-opportunity measures, social-determinants data, and other population-health resources.
The Virginia Cancer Registry, for example, provides geographic information about cancer diagnosis and staging.
Chronic-disease resources provide information about conditions such as high triglycerides, diabetes, cardiovascular disease, hypertension, COPD, and asthma.
And some analyses go beyond simply mapping disease.
They begin connecting disease burden with access to resources.
That's where this gets commercially interesting.
Imagine a geographic area where public-health data suggests a substantial burden of diabetes while access to structured diabetes-management resources varies considerably.
I am a type one diabetic. I live in southwest Virginia; VDH's own diabetes data shows exactly this pattern: the highest diabetes burden in the state is concentrated in Southern Virginia, in some of the same health districts with the lowest density of Diabetes Prevention Program (DPP) and Diabetes Self-Management Education (DSMES) sites. The state didn't just describe the disease; it mapped the disease against the resource gap.
The traditional sales approach might begin:
“Our diabetes technology has these advantages over the incumbent.”
The population-driven Challenger approach could begin somewhere else:
“The state data suggest that this region carries a significant diabetes burden, while access to structured diabetes-management resources varies across the area. What does diabetes management look like for your patients between visits?”
Now we're having a conversation.
Maybe the physician says:
“That's actually a huge problem. We don't have enough diabetes educators.”
Or:
“That's not really what we're seeing.”
Or:
“Our biggest issue is getting patients to come back.”
Every answer teaches the salesperson something.
This open-ended question is the point. We use our data to gather more data, enabling a double-tap, and showing the HCP that we are more concerned about the overall problem than about selling a product.
Don't Sell the Conclusion. Sell the Question.
This may be the most important rule of the entire strategy.
Public-health data should not be used to tell a physician what is happening in their practice.
A health district isn't a physician's patient panel.
A county isn't a patient.
And correlation isn't causation.
As a former researcher, I believe that population data should create a hypothesis.
The salesperson's job is then to turn that hypothesis into a good question.
For example:
Instead of:
“Your area has a screening problem.”
Ask:
“The state data suggest a higher rate of late-stage colorectal cancer in this region. Does that pattern match what you're seeing, and where do you think patients are getting lost between screening and diagnosis?”
The first statement delivers a conclusion.
The second invites clinical expertise.
That's a much better place for a salesperson to start.
The Macro-to-Micro Bridge
This is where I think the strategy becomes most useful.
Population data gives us the macro.
The physician gives us the micro.
The salesperson creates the bridge.
Macro
What is happening in the population?
Place
Is something unusual happening here?
Practice
Does the physician see the same pattern?
Question
Why might it be happening?
Solution
Can the product legitimately address part of that problem?
The product comes last.
Not because products aren't important.
Because in science, relevance is earned through discovery.
What I Would Want a Salesperson to Ask Before Every Call
Before walking into a customer conversation, imagine asking five questions:
1. What is happening in this population?
2. Is there something unusual about this particular geography?
3. What are the possible explanations?
4. What question could I ask this HCP that the data cannot answer?
5. If the problem exists, can my solution legitimately help?
That last question matters.
Because sometimes the answer is no.
And that's okay.
A good Challenger conversation should be willing to discover that the product isn't the answer.
Where This Strategy Works Best
This approach isn't universal.
It is particularly compelling when the problem itself varies geographically or depends on the healthcare system around the patient.
Think about:
Late-stage diagnosis
Screening gaps
Undiagnosed disease
Treatment access
Referral delays
Chronic-disease management
Geographic disparities
Resource shortages
Care fragmentation
Differences in healthcare utilization
These are problems where place matters.
A population-level insight can therefore provide a more meaningful opening than another comparison with a competitor.
Where It Doesn't Work
This isn't a replacement for product differentiation.
A me-too product in a crowded category doesn't automatically become more compelling because someone found an interesting county-level statistic.
If the data doesn't reveal a meaningful problem, don't force it.
If the sample size is too small, don't use it.
If the data is too old, find something better.
If the physician says the pattern doesn't exist in their practice, listen.
The goal isn't to manufacture urgency.
The goal is to discover whether there is a problem worth solving.
The Data Isn't Perfect
Public-health data has limitations.
Some datasets lag behind current conditions.
Small populations can produce unstable rates.
Definitions can differ between datasets, as can the coding of a condition.
Geographic aggregation can hide important differences.
Suppression rules can limit reporting.
And a population-level association doesn't establish causation.
Those aren't reasons to avoid the strategy.
They're reasons to use it responsibly.
The strongest conversation sounds something like:
“This is what the population data suggests. I'm interested in whether you're seeing the same thing.”
That statement is both more intellectually honest and more commercially useful.
Compliance Still Matters
There is another reason to keep the strategy disciplined.
Biopharma and medical-device commercial activity operates within significant regulatory and compliance boundaries.
Population data can support legitimate disease-state education and discussions about unmet needs.
It should not become a mechanism for unsupported clinical conclusions, off-label promotion, or inappropriate treatment recommendations.
The data should open a conversation.
No matter someone's clinical background or education level, population data should never substitute for clinical evidence or professional judgment.
Any customer-facing materials should be developed and reviewed within the appropriate medical, legal, regulatory, and compliance processes.
Why This Matters to Me
Coming from a scientific and HCP teaching background rather than a clinical-practice background, I can't manufacture years of experience sitting in an exam room.
I don't think I should try.
But I can bring something different.
I can understand the science.
I can understand population-level data.
I can understand how commercial organizations translate scientific information into market strategy.
And I can ask whether those pieces can be connected differently at the point where a salesperson actually meets the customer.
That's the opportunity I see.
Not replacing the clinician in the room.
Making the commercial professional better prepared to listen to the clinician in the room.
The Differentiator Isn't Knowing More About the Product
This is where my thinking ultimately landed.
If a hiring manager is choosing between a salesperson who knows a product extremely well, translates science, and has a background training HCP, versus a clinician who has spent years inside the healthcare environment, the clinician has an obvious advantage.
They understand the room.
They understand the workflow and limitations.
They understand the patient.
But perhaps there is another way to create value.
What if the commercial professional walks into that room already understanding something about the population surrounding the practice?
What if they can look at public-health data and recognize a potential problem before the conversation begins?
What if they don't use that information to tell the physician what to think, but instead ask a question worth answering?
That's not clinical experience.
It's a different kind of preparation.
And I think healthcare commercial teams need both.
The Last Mile
The next generation of Challenger selling may not begin with a competitor's weakness.
It may begin with a population's unmet need in healthcare.
The data is already there.
Healthcare organizations already use it.
State departments of health publish it.
The CDC publishes it.
Hospitals publish it.
Researchers analyze it.
Commercial organizations incorporate it into strategy.
The opportunity is to move some of that intelligence one step further.
Into the customer conversation.
A state dashboard can't tell a physician what is happening in their practice, such as the ratio of specialists to regional patients, commute distances, or which clinical gaps are quietly shaping outcomes in ways no claims report will ever surface.
But it can give them a reason to look.
And a salesperson doesn't need to walk into the room with every answer.
They need to walk in prepared to ask a question that matters.
In my opinion, the most valuable thing a commercial professional can bring into a clinical conversation isn't another product claim.
It's a better question.
